skip to content

Cambridge Immunology Network

 
Read more at: Targeting cellular response to SARS-CoV-2 holds promise as new way to fight infection

Targeting cellular response to SARS-CoV-2 holds promise as new way to fight infection

17 June 2021

A new treatment approach focused on fixing cell damage, rather than fighting the virus directly, is effective against SARS-CoV-2 in lab models. If found safe for human use, this anti-viral treatment would make COVID-19 symptoms milder and speed up recovery times. Read the original article here>


Read more at: How mass testing helped limit the spread of COVID-19 at the University of Cambridge.

How mass testing helped limit the spread of COVID-19 at the University of Cambridge.

1 June 2021

A combination of testing programmes for staff and students, infection control measures and genomic surveillance helped reduce the number of cases of COVID-19 at the University of Cambridge and keep the wider community safe. Read the original article here>


Read more at: Cambridge researchers awarded the Millennium Technology Prize

Cambridge researchers awarded the Millennium Technology Prize

18 May 2021

British duo Professor Shankar Balasubramanian and Professor David Klenerman have been awarded the Millennium Technology Prize for their development of revolutionary DNA sequencing techniques. Read the original article here>


Read more at: The Academy of Medical Sciences announces election of new Fellows 2021

The Academy of Medical Sciences announces election of new Fellows 2021

12 May 2021

Cambridge scientists are among the new Fellows announced today by the Academy of Medical Sciences. The Academy of Medical Sciences has elected 50 prominent biomedical and health scientists to its respected and influential Fellowship. The new Fellows have been selected for their exceptional contributions to the advancement...


Read more at: Ability of multi-drug resistant infection to evolve within cystic fibrosis patients highlights need for rapid treatment

Ability of multi-drug resistant infection to evolve within cystic fibrosis patients highlights need for rapid treatment

29 April 2021

Scientists have been able to track how a multi-drug resistant organism is able to evolve and spread widely among cystic fibrosis patients – showing that it can evolve rapidly within an individual during chronic infection. Read the original article here>


Read more at: New cancer algorithm flags genetic weaknesses in tumours

New cancer algorithm flags genetic weaknesses in tumours

27 April 2021

A new way to identify tumours that could be sensitive to particular immunotherapies has been developed using data from thousands of NHS cancer patient samples sequenced through the 100,000 Genomes Project. Read the original article here>


Read more at: Scientists develop new class of cancer drug with potential to treat leukaemia

Scientists develop new class of cancer drug with potential to treat leukaemia

26 April 2021

Scientists have made a promising step towards developing a new drug for treating acute myeloid leukaemia, a rare blood disorder. In a study published today in Nature, Cambridge researchers report a new approach to cancer treatment that targets enzymes which play a key role in translating DNA into proteins and which could...


Read more at: Differing immune reponses discovered in asymptomatic cases versus those with severe COVID-19

Differing immune reponses discovered in asymptomatic cases versus those with severe COVID-19

20 April 2021

Using data from the Human Cell Atlas, researchers have identified the differences in immune cells’ response in those who had no symptoms compared to severe symptoms. The largest study of its type in the UK has identified differences in the immune response to COVID-19, between people with no symptoms, compared to those...


Read more at: Cambridge leads national drug trial to prevent deaths after COVID-19 patients leave hospital

Cambridge leads national drug trial to prevent deaths after COVID-19 patients leave hospital

25 March 2021

A UK-wide study is being launched to reduce the number of people who die in the months following a stay in hospital with COVID-19. The clinical trial - named HEAL-COVID - also aims to cut the number of patients being readmitted to hospital with complications as a result of having COVID. Read the original article here>


Read more at: Cambridge leads trial to see if tapeworm drug can boost protection from COVID-19 among vulnerable

Cambridge leads trial to see if tapeworm drug can boost protection from COVID-19 among vulnerable

23 March 2021

UK researchers are launching a clinical trial to investigate if the drug niclosamide, usually used to treat tapeworms, can prevent COVID-19 infection in vulnerable, high risk kidney patients and reduce the number of people who become seriously ill or die from it. Read the original article here>